Although PD-1/PD-L1 drugs like nivolumab and pembrolizumab have shown therapeutic efficacy in HCC, tumor-intrinsic resistance mechanisms (24) have limited (~20%) response rates even. The gene discussed is CD274; the disease is hepatocellular carcinoma.